BIOMAT Database Logo BIOMAT Database Logo

Quality of life in head and neck cancer patients after treatment with high-dose radiotherapy alone or in combination with cetuximab. 2007

Desmond Curran, and Jordi Giralt, and Paul M Harari, and K Kian Ang, and Roger B Cohen, and Merrill S Kies, and Jacek Jassem, and José Baselga, and Eric K Rowinsky, and Nadia Amellal, and Sylvie Comte, and James A Bonner
Omega Research, Dublin, Ireland. descurran@omega-research.eu.com

OBJECTIVE In this randomized, phase III study, quality of life (QoL) was assessed in patients with locoregionally advanced squamous cell carcinoma of the head and neck (SCCHN) after high-dose radiotherapy alone or in combination with cetuximab. METHODS Patients with stage III or IV nonmetastatic and measurable squamous cell carcinoma of the oropharynx, hypopharynx, or larynx were eligible. QoL was assessed using the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 (EORTC QLQ-C30) and EORTC QLQ Head and Neck Cancer-Specific Module at baseline, week 4, and at months 4, 8, and 12 postbaseline. RESULTS In this study, one of the largest conducted in a population of patients with locoregionally advanced SCCHN, 424 patients received radiotherapy alone (213 patients) or radiotherapy plus cetuximab (211 patients). Radiotherapy/cetuximab significantly improved locoregional control (P = .005) and overall survival (P = .03) compared with radiotherapy alone, without significantly increasing radiotherapy-associated adverse events. The current analysis focused on the impact of cetuximab on the QoL. Compliance with completion of QoL questionnaires was high in both arms. QoL worsened during treatment and improved after cessation of treatment, reaching baseline levels at 12 months. There were no significant differences in QoL scores between the treatment arms. This was particularly notable for global health status/QoL, social functioning, social eating, and social contact. Pretreatment global health status/QoL was identified as a significant prognostic variable in these patients. CONCLUSIONS The addition of cetuximab to radiotherapy significantly improved locoregional control and increased overall survival without adversely affecting QoL.

UI MeSH Term Description Entries
D011379 Prognosis A prediction of the probable outcome of a disease based on a individual's condition and the usual course of the disease as seen in similar situations. Prognostic Factor,Prognostic Factors,Factor, Prognostic,Factors, Prognostic,Prognoses
D011788 Quality of Life A generic concept reflecting concern with the modification and enhancement of life attributes, e.g., physical, political, moral, social environment as well as health and disease. HRQOL,Health-Related Quality Of Life,Life Quality,Health Related Quality Of Life
D002294 Carcinoma, Squamous Cell A carcinoma derived from stratified SQUAMOUS EPITHELIAL CELLS. It may also occur in sites where glandular or columnar epithelium is normally present. (From Stedman, 25th ed) Carcinoma, Epidermoid,Carcinoma, Planocellular,Carcinoma, Squamous,Squamous Cell Carcinoma,Carcinomas, Epidermoid,Carcinomas, Planocellular,Carcinomas, Squamous,Carcinomas, Squamous Cell,Epidermoid Carcinoma,Epidermoid Carcinomas,Planocellular Carcinoma,Planocellular Carcinomas,Squamous Carcinoma,Squamous Carcinomas,Squamous Cell Carcinomas
D006258 Head and Neck Neoplasms Soft tissue tumors or cancer arising from the mucosal surfaces of the LIP; oral cavity; PHARYNX; LARYNX; and cervical esophagus. Other sites included are the NOSE and PARANASAL SINUSES; SALIVARY GLANDS; THYROID GLAND and PARATHYROID GLANDS; and MELANOMA and non-melanoma skin cancers of the head and neck. (from Holland et al., Cancer Medicine, 4th ed, p1651) Cancer of Head and Neck,Head Cancer,Head Neoplasm,Head and Neck Cancer,Head and Neck Neoplasm,Neck Cancer,Neck Neoplasm,Neck Neoplasms,Neoplasms, Upper Aerodigestive Tract,UADT Neoplasm,Upper Aerodigestive Tract Neoplasm,Upper Aerodigestive Tract Neoplasms,Cancer of Head,Cancer of Neck,Cancer of the Head,Cancer of the Head and Neck,Cancer of the Neck,Head Neoplasms,Head, Neck Neoplasms,Neoplasms, Head,Neoplasms, Head and Neck,Neoplasms, Neck,UADT Neoplasms,Cancer, Head,Cancer, Neck,Cancers, Head,Cancers, Neck,Head Cancers,Neck Cancers,Neoplasm, Head,Neoplasm, Neck,Neoplasm, UADT,Neoplasms, UADT
D006304 Health Status The level of health of the individual, group, or population as subjectively assessed by the individual or by more objective measures. General Health,General Health Level,General Health Status,Level of Health,Overall Health,Overall Health Status,General Health Levels,Health Level,Health Level, General,Health Levels,Health Status, General,Health Status, Overall,Health, General,Health, Overall,Level, General Health,Levels, General Health,Status, General Health,Status, Health,Status, Overall Health
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068818 Cetuximab A chimeric monoclonal antibody that functions as an ANTINEOPLASTIC AGENT through its binding to the EPIDERMAL GROWTH FACTOR RECEPTOR, where it prevents the binding and signaling action of cell growth and survival factors. C225,Erbitux,IMC C225,IMC-C225,MAb C225
D000911 Antibodies, Monoclonal Antibodies produced by a single clone of cells. Monoclonal Antibodies,Monoclonal Antibody,Antibody, Monoclonal
D000970 Antineoplastic Agents Substances that inhibit or prevent the proliferation of NEOPLASMS. Anticancer Agent,Antineoplastic,Antineoplastic Agent,Antineoplastic Drug,Antitumor Agent,Antitumor Drug,Cancer Chemotherapy Agent,Cancer Chemotherapy Drug,Anticancer Agents,Antineoplastic Drugs,Antineoplastics,Antitumor Agents,Antitumor Drugs,Cancer Chemotherapy Agents,Cancer Chemotherapy Drugs,Chemotherapeutic Anticancer Agents,Chemotherapeutic Anticancer Drug,Agent, Anticancer,Agent, Antineoplastic,Agent, Antitumor,Agent, Cancer Chemotherapy,Agents, Anticancer,Agents, Antineoplastic,Agents, Antitumor,Agents, Cancer Chemotherapy,Agents, Chemotherapeutic Anticancer,Chemotherapy Agent, Cancer,Chemotherapy Agents, Cancer,Chemotherapy Drug, Cancer,Chemotherapy Drugs, Cancer,Drug, Antineoplastic,Drug, Antitumor,Drug, Cancer Chemotherapy,Drug, Chemotherapeutic Anticancer,Drugs, Antineoplastic,Drugs, Antitumor,Drugs, Cancer Chemotherapy
D061067 Antibodies, Monoclonal, Humanized Antibodies from non-human species whose protein sequences have been modified to make them nearly identical with human antibodies. If the constant region and part of the variable region are replaced, they are called humanized. If only the constant region is modified they are called chimeric. INN names for humanized antibodies end in -zumab. Antibodies, Humanized,Humanized Antibodies

Related Publications

Desmond Curran, and Jordi Giralt, and Paul M Harari, and K Kian Ang, and Roger B Cohen, and Merrill S Kies, and Jacek Jassem, and José Baselga, and Eric K Rowinsky, and Nadia Amellal, and Sylvie Comte, and James A Bonner
Cisplatin alone or in combination with adriamycin in the treatment of patients with head and neck cancer relapsed after radiotherapy and/or surgery.
January 1981, Revista espanola de oncologia,
Desmond Curran, and Jordi Giralt, and Paul M Harari, and K Kian Ang, and Roger B Cohen, and Merrill S Kies, and Jacek Jassem, and José Baselga, and Eric K Rowinsky, and Nadia Amellal, and Sylvie Comte, and James A Bonner
Changing quality of life in patients with advanced head and neck cancer after primary radiotherapy or chemoradiation.
January 2005, Oncology,
Desmond Curran, and Jordi Giralt, and Paul M Harari, and K Kian Ang, and Roger B Cohen, and Merrill S Kies, and Jacek Jassem, and José Baselga, and Eric K Rowinsky, and Nadia Amellal, and Sylvie Comte, and James A Bonner
Cetuximab: head and neck cancers: for second-line treatment, in combination with radiotherapy.
February 2008, Prescrire international,
Desmond Curran, and Jordi Giralt, and Paul M Harari, and K Kian Ang, and Roger B Cohen, and Merrill S Kies, and Jacek Jassem, and José Baselga, and Eric K Rowinsky, and Nadia Amellal, and Sylvie Comte, and James A Bonner
Incidence of second primary cancers after radiotherapy combined with platinum and/or cetuximab in head and neck cancer patients.
June 2019, Strahlentherapie und Onkologie : Organ der Deutschen Rontgengesellschaft ... [et al],
Desmond Curran, and Jordi Giralt, and Paul M Harari, and K Kian Ang, and Roger B Cohen, and Merrill S Kies, and Jacek Jassem, and José Baselga, and Eric K Rowinsky, and Nadia Amellal, and Sylvie Comte, and James A Bonner
Quality of life after radical radiotherapy for prostate cancer: longitudinal study from a randomised trial of external beam radiotherapy alone or in combination with high dose rate brachytherapy.
May 2013, Clinical oncology (Royal College of Radiologists (Great Britain)),
Desmond Curran, and Jordi Giralt, and Paul M Harari, and K Kian Ang, and Roger B Cohen, and Merrill S Kies, and Jacek Jassem, and José Baselga, and Eric K Rowinsky, and Nadia Amellal, and Sylvie Comte, and James A Bonner
Phase I trial of pemetrexed in combination with cetuximab and concurrent radiotherapy in patients with head and neck cancer.
November 2011, Annals of oncology : official journal of the European Society for Medical Oncology,
Desmond Curran, and Jordi Giralt, and Paul M Harari, and K Kian Ang, and Roger B Cohen, and Merrill S Kies, and Jacek Jassem, and José Baselga, and Eric K Rowinsky, and Nadia Amellal, and Sylvie Comte, and James A Bonner
Cetuximab and radiotherapy for head and neck cancer.
February 2006, The New England journal of medicine,
Desmond Curran, and Jordi Giralt, and Paul M Harari, and K Kian Ang, and Roger B Cohen, and Merrill S Kies, and Jacek Jassem, and José Baselga, and Eric K Rowinsky, and Nadia Amellal, and Sylvie Comte, and James A Bonner
Quality of life and salivary output in patients with head-and-neck cancer five years after radiotherapy.
January 2007, Radiation oncology (London, England),
Desmond Curran, and Jordi Giralt, and Paul M Harari, and K Kian Ang, and Roger B Cohen, and Merrill S Kies, and Jacek Jassem, and José Baselga, and Eric K Rowinsky, and Nadia Amellal, and Sylvie Comte, and James A Bonner
Cetuximab plus radiotherapy for head and neck cancer.
May 2006, The New England journal of medicine,
Desmond Curran, and Jordi Giralt, and Paul M Harari, and K Kian Ang, and Roger B Cohen, and Merrill S Kies, and Jacek Jassem, and José Baselga, and Eric K Rowinsky, and Nadia Amellal, and Sylvie Comte, and James A Bonner
Cetuximab plus radiotherapy for head and neck cancer.
May 2006, The New England journal of medicine,
Copied contents to your clipboard!